Fusidic Acid

Phase 3Small molecule

Roche

Fusidic Acid is one of 11 small molecule programs targeting Cutaneous Leishmaniasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous LeishmaniasisNot yet recruiting

Cutaneous LeishmaniasisPhase 3

Not yet recruiting

Competition

Competitive Landscape

15 competitors in Cutaneous Leishmaniasis

#DrugCompanyPhaseTrials

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Garamycin

Levaquin

Impavido

KKnight Therapeutics (USA) Inc

Phase 3

12 5

Trental

VValidus Pharmaceuticals

Phase 3

3 6

Flagyl

DDePuy Orthopaedics

Phase 2

1 7

Meglumine Antimoniate

UUniversity of Brasilia

Phase 3

14 8

Arnica Tincture

UUniversidad de Antioquia

Phase 3

2 9

Fusidic Acid

Roche

Phase 3

1 10

LXE408

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Cutaneous Leishmaniasis

NCT06695143

Clinical

Trials by Indication[1]

Cutaneous Leishmaniasis1 trial

Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia

Not yet recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT06695143·180 enrolled

Age1 trial

A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.

Completed· Roche logo

Roche·Phase 3·NCT00718315·201 enrolled

Catheter1 trial

Scars After Central Venous Catheters

Unknown status·MMette Møller Handrup·Phase 3·NCT01113125·60 enrolled

Colonization1 trial

S. Aureus Decolonization in HPN Patients.

Terminated·RRadboud University Medical Center·N/A·NCT03173053·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Fusidic Acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fusidic Acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fusidic Acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Fusidic Acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cutaneous Leishmaniasis1 trial

Age1 trial

Catheter1 trial

Colonization1 trial

References

Drug Info

Quick Facts

Related News